A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.

<h4>Background</h4>Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiyoshi Masuda, Shigetada Teshima-Kondo, Mina Mukaijo, Naoko Yamagishi, Yoshiko Nishikawa, Kensei Nishida, Tomoko Kawai, Kazuhito Rokutan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2008
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/2fb82b43a47c43e0b07742d512213682
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2fb82b43a47c43e0b07742d512213682
record_format	dspace
spelling	oai:doaj.org-article:2fb82b43a47c43e0b07742d5122136822021-11-25T05:36:57ZA novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.1549-12771549-167610.1371/journal.pmed.0050094https://doaj.org/article/2fb82b43a47c43e0b07742d5122136822008-05-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18494554/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells.<h4>Methods and findings</h4>Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 5'UTRs. Using these plasmids, we revealed that the 5'UTR of vegf mRNA possessed anti-apoptotic activity. The 5'UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 5'UTR or the mutated 5'UTR. The clones expressing the 5'UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 5'UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 5'UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)alpha therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNalpha responses.<h4>Conclusions</h4>These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.Kiyoshi MasudaShigetada Teshima-KondoMina MukaijoNaoko YamagishiYoshiko NishikawaKensei NishidaTomoko KawaiKazuhito RokutanPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 5, Iss 5, p e94 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Kiyoshi Masuda Shigetada Teshima-Kondo Mina Mukaijo Naoko Yamagishi Yoshiko Nishikawa Kensei Nishida Tomoko Kawai Kazuhito Rokutan A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
description	<h4>Background</h4>Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells.<h4>Methods and findings</h4>Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 5'UTRs. Using these plasmids, we revealed that the 5'UTR of vegf mRNA possessed anti-apoptotic activity. The 5'UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 5'UTR or the mutated 5'UTR. The clones expressing the 5'UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 5'UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 5'UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)alpha therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNalpha responses.<h4>Conclusions</h4>These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.
format	article
author	Kiyoshi Masuda Shigetada Teshima-Kondo Mina Mukaijo Naoko Yamagishi Yoshiko Nishikawa Kensei Nishida Tomoko Kawai Kazuhito Rokutan
author_facet	Kiyoshi Masuda Shigetada Teshima-Kondo Mina Mukaijo Naoko Yamagishi Yoshiko Nishikawa Kensei Nishida Tomoko Kawai Kazuhito Rokutan
author_sort	Kiyoshi Masuda
title	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
title_short	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
title_full	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
title_fullStr	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
title_full_unstemmed	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
title_sort	novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mrna.
publisher	Public Library of Science (PLoS)
publishDate	2008
url	https://doaj.org/article/2fb82b43a47c43e0b07742d512213682
work_keys_str_mv	AT kiyoshimasuda anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT shigetadateshimakondo anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT minamukaijo anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT naokoyamagishi anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT yoshikonishikawa anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT kenseinishida anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT tomokokawai anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT kazuhitorokutan anoveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT kiyoshimasuda noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT shigetadateshimakondo noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT minamukaijo noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT naokoyamagishi noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT yoshikonishikawa noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT kenseinishida noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT tomokokawai noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna AT kazuhitorokutan noveltumorpromotingfunctionresidinginthe5noncodingregionofvascularendothelialgrowthfactormrna
_version_	1718414568454094848

A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.

Ejemplares similares